Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publikationen 2011

Originalarbeiten

  • Hübel K, Weingart O, Naumann F, Bohlius J, Fresen M, Engert A, Wheatley K. Allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia: A systmatic analysis of international guidelines and recommendations. Leukemia & Lymphoma Mar 52(3):444-457 (2011)
  • Borchmann P, Herbrecht R, Wilhelm M, Morschhauser F, Hess G, Cernohous P, Veals SA, Singer JW, Engert A. Phase I/II study of Pixantrone in combination with Cyclophosphamide, Vincristine and Prednisone (CPOP) in patients with relapsed aggressive Non Hodgkin Lymphoma. Leukemia & Lymphoma 52(4):620-628 (2011)
  • Patrij K, Reiser M, Wätzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, Vogt-Schaden M, Egerer G, Lamprecht M, Batchelor T, Schlegel U, Schmidt-Wolf I. Isolated central nevous system relapse of systemic lymphoma (SCNSL): Clinical features and outcome of a retrospective analysis. Ger Med Sci (German Medical Sience) Vol 9:Doc11 (2011)
  • Straka C, Sandherr M, Salwender H, Wandt H, Metzner B, Huebel K, Silling G, Hentrich M, Franke D, Schwerdtfeger R, Freund M, Sezer O, Giagounidis A, Ehninger G, Grimminger W, Engert A, Schlimock G, Scheid C, Hellmann G, Heinisch H, Einsele H, Hinke A, Emmerich B. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. Blood. Feb 17;117(7):2121-8 (2011)
  • Draube A, Klein-Gonzales N, Mattheus S, Brillant C, Hellmich M, Engert A, von Bergwelt-Baildon M. Dendritic-cell based tumor vaccination in prostate and renal cell cancer: A systematic review and meta-analysis. PLoS One Apr 20;6(4):e18801 (2011)
  • Jachimowicz R, Fracasso G, Yazaki PJ, Power BE, Borchmann P, Engert A, Hansen HP, Reiners K, Pogge von Strandmann E, Rothe A. Induction of in vitro and in vivo NK cells cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma. Mol Cancer Ther Jun;10(6):1036-45 (2011)
  • Deckert M, Engert A, Brück W, Ferreri AJM, Finke J, Illerhaus G, Klapper W, Korfel A, Küppers R, Maarouf M, Montesinos-Rongen M, Paulus W, Schlegel U, Lassmann H, Wiestler OD, Siebert R, , DeAngelis LM. Modern concepts in the biology, diagosis, differential diagnosis and treatment of primary lymphoma of the central nervous system. Leukemia 25:1797-1807 (2011)
  • Scholz M, Engert A, Franklin J, Josting A, Diehl V, Hasenclever D, Loeffler M. Impact of first and second line treatment for Hodgkin’s lymphoma of the incidence of AML/MDS and NHL – Experience of the German Hodgkin’s Lymphoma Study Group analysed by a parametric model. Ann Oncol Mar;22(3):681-88 (2011)
  • Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Böll B, von Tesckow B, Nogova L, Borchmann P, Engert A. Phase II study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood Oct 20(118)16:4363-65 (2011)
  • Klimm B, Franklin J, Stein H, Eichenauer DA, Haverkamp H, Diehl V, Fuchs M, Bochmann P, Engert A. Lymphocyte-depleted classical Hodgkin lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 29(29);10:3914-20 (2011)
  • Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG) J Clin Oncol Nov 10;29(32):4234-42 (2011)
  • Borchmann P, Diehl V, Engert A. ABVD versus BEACOPP for Hodgkins lymphoma. New Engl J Med Oct 20(36);16:1544-6 (2011)
  • Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, Kyrcz-Krzemien S, Vatutin M, Wu J, Sirard C, Hallek M, Engert A. Fludarabine plus Alemtuzumab versus Fludarabine alone in patients with previously treated chronic lymphocytic leukemia: a randomised phase 3 trial. Lancet Oncol 12:1204-13 (2011)
  • Böll B, Bredenfeld H, Görgen H, Halbsguth T, Eich HT, Soekler M, Markova J, Keller U, Graeven U, Kremers S, Geissler M, Trenn G, Fuchs M, von Tresckow B, Eichenauer D, Borchmann P, Engert A. Phase II study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin Lymphoma. Blood Dec 8;118(24):6292-8 (2011)

Übersichtsarbeiten

  • Herbst C, Engert A. Meta analyses of early-stage Hodgkin Lymphoma. Acta Haematologica 125:32-38 (2011)
  • Skoetz N, Kluge S, Monsef I, Bauer K, Siebert H, Kreuzer KA, Engert A. Twelfth biannual report of the Cochrane Haematological Malignancies Group – Focus on Tyrosine Kinase Inhibitors. J Natl Cancer Inst  Feb16;103(4):E1 (2011)
  • Eichenauer DA, Engert A. One size for all in Hodgkin lymphoma? Inside Blood. Blood Mar 3;117(9):2557-8 (2011)
  • Bauer K, Rancea M, Schmidtke B, Kluge S, Monsef I, Hübel K, Engert A, Skoetz N. Thirteenth biannual report of the Cochrane Haematological Malignancies Group – Focus on Multiple Myeloma. J Natl Cancer Inst Sep 7;103(17):E1-19 (2011)
  • Von Tresckow B, Engert A. The role of autologous transplantation in Hodgkin Lymphoma. Curr Hematol Malig Rep 6:172-9 (2011)
  • Ullrich K, Wurster KD, Lamprecht B, Köchert K, Engert A, Dörken B, Janz M, Mathas S. BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines. Br J Heamatol Nov;155(3):398-402 (2011)
  • Borchmann P, Engert A, Diehl V. Hodgkin lymphoma-absence of evidence not evidence of absence! Nat Rev Clin Oncol 8:636-7 (2011)
  • Engert A. How should we treat nodular lymphocyte-predominant Hodgkin lymphoma? The ASCO Post Dec 15, 2(18) (2011) 
  • Eichenauer DA, Engert A. Therapy-related myeloid neoplasms in patients treated for Hodgkin lymphoma. Mediterr J Hematol Infect Dis Oct 24;3(1):e2011046 (2011) 
  • Engert A. Stellenwert der Positronen-Emissions-Tomographie bei Patienten mit malignen Lymphomen. KML-Newletter 19, Juli  (2011)
  • Vetter M, Tzankov A, Engert A, Mehling M, Herrmann R, Rochlitz C. Hodgkin lymphoma and paraneoplastic phenomena in the CNS. A case report and review of the literature. Case Rep Oncol 4:106–114 (2011)